HERON THERAPEUTICS, INC. /DE/ — Director's Dealing 2021

Apr 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK: 0000818033
Period of Report: 2021-04-13

Reporting Person: Szekeres David Leslie (EVP, Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-13	Common Stock	M	1250	—	Acquired	1250	Direct
2021-04-13	Common Stock	F	433	$16.66	Disposed	817	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-13	Restricted Stock Units	$	M	1250	Disposed		Common Stock (1250)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

F3: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020).